Hamid Sayar - Concepedia

Author

Hamid Sayar

Indiana University – Purdue University Indianapolis ORCID

Also Known As

H Sayar, H. Sayar, Hamid Sayar, Sayar,Hamid

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Indiana University – Purdue University Indianapolis The University of Texas MD Anderson Cancer Center Indiana University Melvin and Bren Simon Comprehensive Cancer Center Cornell University Monash University

About

Hamid Sayar is an author at Indiana University – Purdue University Indianapolis specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	274
2	Health Sciences	3	3	262
3	Language Studies	1	1	422
4	East Asian Languages	1	1	422
5	Emergency Medicine	1	1	12

Hamid Sayar

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Where West Meets East: The Complex mtDNA Landscape of the Southwest and Central Asian Corridor Lluís Quintana‐Murci, Raphaëlle Chaix, R. Spencer Wells, The American Journal of Human Genetics Historical GeographySouth Asian CultureEast Asian StudiesArchaeologyEast Asian Languages	2004	422
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission Andrew H. Wei, Hartmut Döhner, Christopher Pocock, New England Journal of Medicine	2020	403
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, The Lancet Oncology Hematological MalignancyMedicineHematologyClinical TrialsPharmacology	2015	153
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission Andrew H. Wei, Hartmut Döhner, Christopher Pocock, Blood	2019	97
Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study Guillermo Garcia‐Manero, Yasmin Abaza, Koichi Takahashi, Blood Advances	2019	86
Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML) Harry P. Erba, Hamid Sayar, Mark Juckett, Investigational New Drugs Hematological MalignancyOncologyMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2013	71
Design of the Randomized, Phase III, QUAZAR AML Maintenance Trial of CC-486 (Oral Azacitidine) Maintenance Therapy in Acute Myeloid Leukemia Gail J. Roboz, Pau Montesinos, Dominik Selleslag, Future Oncology Hematological MalignancyEpigenetic RegulationMedicineAcute Myeloid LeukemiaPhase Iii	2016	38
A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses <i>DAPK1</i> in Acute Myeloid Leukemia Rajasubramaniam Shanmugam, Padmaja Gade, Annique Wilson-Weekes, Clinical Cancer Research	2011	37
Improved Survival in Patients with First Relapsed or Refractory Acute Myeloid Leukemia (AML) Treated with Vosaroxin Plus Cytarabine Versus Placebo Plus Cytarabine: Results of a Phase 3 Double-Blind Randomized Controlled Multinational Study (VALOR) Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar, Blood	2014	23
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial Farhad Ravandi, Gail J. Roboz, Andrew H. Wei, Journal of Hematology & Oncology	2021	21

Page 1